Molecular underpinning of light therapy in seasonal affective disorder

Molecular underpinning of light therapy in seasonal affective disorder - Light increases cellular excitability

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON37640

Enrollment

Registered

2011-12-06

Start date

2012-01-13

Completion date

Unknown

Last updated

2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

circadiane ritme stoornissen, vermindering van celactiviteit nivo seasonal affective disorder winterdepression

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: SAD patients and healthy sex/age matched controls

Exclusion criteria

Exclusion criteria: Healthy control group: Symptoms of possible sleep disorder, time zone transmeridian flights (or more) one month prior to taking part in the study, Shift work during the last 3 months, Colour blindness, Eye diseases, Somatic and psychiatric diseases (no indications of depressed mood), History of chronic diseases, Excessive daily amount of caffeinated drinks, Alcohol and drug problems, Regular medication during past 3 months. Large to moderate seasonal fluctuations in social behaviour, sleep and food intake, any indication of seasonal variation in mood. Patients group: Other AS-I disorders on DSM-IV than for the inclusion selection, Risk of committing suicide, Use of mood changing or photic sensitizing medication, Eye diseases, colour blindness, shift workers, recent travels across two time zones or more, large changes in daily light expose (no travelling to sunny areas, use of any artificial sun/tanning machines) other than for the treatment of winter depression

Design outcomes

Primary

Measure	Time frame
The effect of a 1.5 hour light pulse will be determined on the degree of melatonin suppression. The variance in individual responses in melatonin suppression (in vivo) will be compared within each individual with the variance in the degree of fibroblast cellular excitability (in vitro). Differences between healthy controls and SAD patients for this relationship will be determined. The variance in in vivo and in vitro measurements in SAD patients will be compared to light therapy success.	—

Measure

Time frame

The effect of a 1.5 hour light pulse will be determined on the degree of melatonin suppression. The variance in individual responses in melatonin suppression (in vivo) will be compared within each individual with the variance in the degree of fibroblast cellular excitability (in vitro). Differences between healthy controls and SAD patients for this relationship will be determined. The variance in in vivo and in vitro measurements in SAD patients will be compared to light therapy success.

—

Secondary

Measure	Time frame
Analysis of inter-individual differences in non-visual light sensitivity measured as melatonin suppression in SAD patients and healthy controls and link individual characteristics of light sensitivity and the molecular pathways involved to light treatment efficiency in SAD patients. In addition gene variation in genes involved in light sensitivity (OPN4) and cellular excitability (adenylyl cyclase) will be related with the in vivo and in vitro measures.	—

Measure

Time frame

Analysis of inter-individual differences in non-visual light sensitivity measured as melatonin suppression in SAD patients and healthy controls and link individual characteristics of light sensitivity and the molecular pathways involved to light treatment efficiency in SAD patients. In addition gene variation in genes involved in light sensitivity (OPN4) and cellular excitability (adenylyl cyclase) will be related with the in vivo and in vitro measures.

—

Countries

Netherlands

Outcome results